Floatz logo

ALECTINIB

Central Nervous System

Hoffmann-La RocheSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Central Nervous System cohort.

Asset / SponsorPhaseRating
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules
Beijing Friendship Hospital
Phase 4BB
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4BB
3-N-BUTYLPHTHALIDE
Qianfoshan Hospital
Phase 4BB
ENCENICLINE
FORUM Pharmaceuticals Inc
Phase 2BB
Donanemab
Eli Lilly and Company
Phase 3BB

View all 50 →

Same molecule, other indications

ALECTINIB is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
Drug MonitoringDormant
BB
Indicative ·
65 / 100
View asset →
Anaplastic Lymphoma Kinase Gene MutationDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →